Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 1996 Feb;72(2):83-4.
doi: 10.1007/BF00641313.

Allogeneic bone marrow transplatation in a patient with Shwachman-Diamond syndrome

Affiliations
Case Reports

Allogeneic bone marrow transplatation in a patient with Shwachman-Diamond syndrome

L Arseniev et al. Ann Hematol. 1996 Feb.

Abstract

Shwachman-Diamond syndrome (SDS) is a rare inherited disorder involving concomitant neutropenia and exocrine pancreatic insufficiency. About 25% of patients develop hematopoietic malignancies. We describe a 24-year-old male patient with SDS who underwent allogeneic bone marrow transplantation (BMT) because of progression into acute myeloid leukemia (AML) following myelodysplastic syndrome (MDS). The BMT preparative regimen consisted of busulfan (16 mg/kg body wt.), followed by cyclophosphamide (120 mg/kg). Cyclosporin A and short methotrexate were used for graft-versus-host disease (GvHD) prophylaxis. The post-transplant period was complicated by staphylococcal septicemia, CMV infection, renal insufficiency, and acute GvHD grade III. Hematological recovery was delayed (post-transplant day +55). The patient was discharged at day +68 in complete remission without any evidence of MDS. RFLP fingerprint analysis showed complete engraftment of the donor's hematopoiesis. The patient's leukemia relapsed 9 months post-transplant, and death followed due to CMV infection and multiorgan failure. Despite the fatal course in this patient, allogeneic BMT could be an option for curative treatment of the hematopoietic failure in SDS. The interaction of BMT with pancreatic insufficiency still has to be ascertained.

PubMed Disclaimer

References

    1. Arch Dermatol. 1991 Feb;127(2):225-30 - PubMed
    1. Presse Med. 1985 Jan 12;14(1):45 - PubMed
    1. Arch Dis Child. 1990 Dec;65(12):1349-52 - PubMed
    1. Blood. 1993 Jul 15;82(2):677-81 - PubMed
    1. Am J Pediatr Hematol Oncol. 1990 Winter;12(4):472-6 - PubMed

Publication types